Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
Name:
Barros-Martins et al.pdf
Size:
8.416Mb
Format:
PDF
Description:
Open Access publication
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Barros-Martins, JoanaHammerschmidt, Swantje I
Cossmann, Anne
Odak, Ivan
Stankov, Metodi V
Morillas Ramos, Gema
Dopfer-Jablonka, Alexandra
Heidemann, Annika
Ritter, Christiane
Friedrichsen, Michaela
Schultze-Florey, Christian
Ravens, Inga
Willenzon, Stefanie
Bubke, Anja
Ristenpart, Jasmin
Janssen, Anika
Ssebyatika, George
Bernhardt, Günter
Münch, Jan
Hoffmann, Markus
Pöhlmann, Stefan
Krey, Thomas
Bošnjak, Berislav
Förster, Reinhold
Behrens, Georg M N
Issue Date
2021-07-14
Metadata
Show full item recordAbstract
Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca's ChAdOx1-nCov-19 (ChAd) only in individuals older than 60 years, leaving millions of already ChAd-primed individuals with the decision to receive either a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School's COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd (n = 32) or BioNTech/Pfizer's BNT162b2 (n = 55). Although both vaccines boosted prime-induced immunity, BNT162b2 induced significantly higher frequencies of spike-specific CD4+ and CD8+ T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants of concern of severe acute respiratory syndrome coronavirus 2.Citation
Barros-Martins, J., Hammerschmidt, S.I., Cossmann, A. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med 27, 1525–1529 (2021). https://doi.org/10.1038/s41591-021-01449-9Affiliation
CiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.Publisher
NatureJournal
Nature medicinePubMed ID
34262158Type
ArticleLanguage
enEISSN
1546-170Xae974a485f413a2113503eed53cd6c53
10.1038/s41591-021-01449-9
Scopus Count
The following license files are associated with this item:
- Creative Commons